Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects
The publisher, authors, editors, syndication partners, and all distribution platforms make no warranties or representations regarding the completeness, accuracy, or reliability of the information and expressly disclaim any and all liability for any losses, damages, or harm resulting from the use or misuse of any product referenced in this content
Some coverage can be verified by searching, though clearer sourcing would improve transparency
Employers should cover all evidence-based obesity care options, including drugs, nutrition therapy, behavioral health services and surgery, the groups say